<SEC-DOCUMENT>0001564590-22-005777.txt : 20220222
<SEC-HEADER>0001564590-22-005777.hdr.sgml : 20220222
<ACCEPTANCE-DATETIME>20220222073728
ACCESSION NUMBER:		0001564590-22-005777
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220222
FILED AS OF DATE:		20220222
DATE AS OF CHANGE:		20220222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MESOBLAST LTD
		CENTRAL INDEX KEY:			0001345099
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37626
		FILM NUMBER:		22655002

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
		BUSINESS PHONE:		613 9639 6036

	MAIL ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>meso-6k_20220221.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
meso-6k_20220221.htm
</title>
</head>
<!-- NG Converter v5.0.2.70 -->
<body>

<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:91.55%;">
<tr>
<td style="width:468pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:double 3pt #000000;">
<p style="margin-top:5pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;;font-size:15pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:36pt;;">UNITED STATES <br />SECURITIES AND EXCHANGE COMMISSION</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:3pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:18pt;">Form&#160;6-K</font><font style="font-size:18pt;font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Foreign Private Issuer<br />Pursuant to Rule&#160;13a-16 or 15d-16 under the Securities Exchange Act of 1934<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the month of February 2022</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number 001-37626</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Exact name of Registrant as specified in its charter</font>)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Translation of Registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia<font style="font-weight:normal;"><br />(</font><font style="font-style:italic;font-weight:normal;">Jurisdiction of incorporation or organization)</font></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Silviu Itescu</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Executive Director</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Australia </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Address of principal executive offices</font>)</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F:</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;20-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font> Form&#160;40-F <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font> No <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font> No <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="glqsvqcpzqcz000001.jpg" title="" alt="" style="width:0px;height:2px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 21, 2022, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement which is attached hereto as <font style="text-decoration:underline;">Exhibit 99.1</font>, and is incorporated herein by reference.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES<font style="font-weight:normal;"> </font></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:120.28%;">
<tr>
<td valign="bottom"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.76%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:35.38%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.76%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:8.82%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:29.4pt;;text-indent:-29.4pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:29.4pt;;text-indent:-29.4pt;;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Mesoblast Limited</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Niva Sivakumar</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Niva Sivakumar</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:52.26%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Company Secretary</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: February 22, 2022</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO EXHIBITS</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:93.64%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:3.74%;white-space:nowrap;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:9pt;">
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Press release of Mesoblast Ltd, dated February 21, 2022.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.74%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.62%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>meso-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
meso-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.70 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:48.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2x3wb0evosm000001.jpg" title="" alt="" style="width:242px;height:30px;"></p></td>
<td valign="top"  style="width:47.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2x3wb0evosm000002.jpg" title="" alt="" style="width:277px;height:53px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">RAPID IMPROVEMENT AND REMISSION IN PATIENTS WITH REFRACTORY ULCERATIVE COLITIS AND CROHN&#8217;S COLITIS AFTER DIRECT INJECTION OF REMESTEMCEL-L BY COLONOSCOPY </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Verdana;text-transform:none;font-variant: normal;">Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn&#8217;s and Colitis Organisation (ECCO)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">Melbourne, Australia; February 21, and New York, USA; February 20, 2022: <font style="font-weight:normal;">Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to areas of inflammation in patients with medically refractory ulcerative colitis or Crohn&#8217;s colitis. A single local delivery of remestemcel-L by colonoscopy resulted in rapid mucosal healing and disease remission in these refractory patients at high risk of progression to surgery.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of the first cohort of patients were presented at the 17<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Congress of European Crohn&#8217;s and Colitis Organisation (ECCO), February 16-19, by the trial&#8217;s lead investigator Dr. Amy L. Lightner, Associate Professor of Surgery in the Department of Colon and Rectal Surgery at Cleveland Clinic and were published in the <font style="font-style:italic;">Journal of Crohn's and Colitis.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">1,2</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Mesenchymal stromal cells (remestemcel-L) offer a safe therapeutic for the treatment of medically refractory Ulcerative Colitis and Crohn&#8217;s colitis,&#8221; said Dr. Lightner. &#8220;Early data suggests improved clinical and endoscopic scores as early as two weeks following remestemcel-L delivery.&#8221; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The study at Cleveland Clinic <font style="color:#211D1E;">will randomize up to 48 patients with medically refractory ulcerative colitis or Crohn&#8217;s colitis in a 2:1 fashion to receive a single intervention with remestemcel-L at a dose of 150-300 million cells or placebo delivered via direct injection using a 23 G sclerotherapy needle at the time of colonoscopy. Medically refractory ulcerative colitis and Crohn&#8217;s colitis patients are defined as having active disease for at least 6 months and having lost response to at least one monoclonal antibody (anti-TNF or anti-integrin).</font> M<font style="color:#211D1E;">edically refractory Crohn&#8217;s colitis patients exclude small bowel involvement and colorectal strictures.</font> Outcomes <font style="color:#211D1E;">are evaluated by validated endoscopic and clinical scoring systems at 2 weeks, 6 weeks, and 3 months post intervention.</font><sup style="font-size:85%;line-height:120%;vertical-align:top">3,4</sup></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key results of the <font style="color:#211D1E;">interim analysis performed in the first 12 enrolled patients were as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Colonoscopic delivery of remestemcel-L was not associated with any treatment-related adverse events </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">All ulcerative colitis patients treated with remestemcel-L had improved clinical and endoscopy scores within two weeks, as defined by the Mayo clinical score and Mayo endoscopic severity (MES) score, and all achieved clinical and endoscopic remission by six weeks </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">All ulcerative colitis patients were extremely satisfied or satisfied with remestemcel-L treatment at three months, based on the inflammatory bowel disease patient reported treatment impact (IBD-PRTI), and response was described as excellent or good in all patients</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">All Crohn&#8217;s colitis patients treated with remestemcel-L showed treatment remissions or responses by three months, as measured by the Simple Endoscopy Score for Crohn&#8217;s Disease (SES-CD) (mean score 17 at baseline decreased to 5 at three months) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Remestemcel-L treatment resulted in reduction of fecal calprotectin, a validated biomarker of disease activity,<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> from mean of 231 at baseline to 67 at three months, indicative of remission </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">In controls with ulcerative colitis and Crohn&#8217;s colitis over three months, endoscopy scores increased, fecal calprotectin levels increased from a mean of 330 to 505, and clinical responses were described as poor or unchanged </font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk96282646"></a>Mesoblast Chief Medical Officer, Dr. Eric Rose said, &#8220;We are delighted to be involved with Dr. Lightner and her team at Cleveland Clinic in this latest cutting-edge study. This randomized controlled trial is the first to evaluate local delivery of remestemcel-L directly into the inflamed colon, using objective endoscopic measures of mucosal healing, in patients with colitis who are at high risk of surgical resection of their colon.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:63.8pt;">
<td valign="top"  style="width:10.16%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<br /><font style="font-weight:normal;">ABN 68 109 431 870</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.mesoblast.com</font></p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Headquarters</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Australia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;"> </font><font style="font-size:7pt;font-weight:normal;">+61 3 9639 6036</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +61 3 9639 6030</font></p></td>
<td valign="top"  style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">United States Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505 Fifth Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2060</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2061</font></p></td>
<td valign="top"  style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Asia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Biopolis Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#01-22 Nucleos (South Tower)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SINGAPORE 138567</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +65 6570 0635</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +65 6570 0176</font></p></td>
<td valign="top"  style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="top"  BGCOLOR="#1266AE" style="width:10.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">About Inflammatory Bowel Disease</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to recent estimates, more than three million people (1.3%) in the US alone have inflammatory bowel disease, with more than 33,000 new cases of Crohn&#8217;s disease and 38,000 new cases of ulcerative colitis diagnosed every year.<sup style="font-size:85%;line-height:120%;vertical-align:top">6-8</sup> Despite recent advances, approximately 30% of patients are primarily unresponsive to anti-TNF&#945; agents and even among responders, up to 10% will lose their response to the drug every year. Up to 80% of patients with medically-refractory Crohn&#8217;s disease and 20% of patients with medically-refractory ulcerative colitis eventually require surgical treatment of their disease,<sup style="font-size:85%;line-height:120%;vertical-align:top">9,10</sup> which can have a devastating impact on quality of life.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">About Objective Measures of Disease Activity in Patients with Inflammatory Bowel Disease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Objective measurement of disease activity can be achieved by endoscopy, histopathology, imaging, and biomarkers.<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup> Fecal calprotectin is a very sensitive biomarker for inflammation in the gastrointestinal tract, with the presence of calprotectin a result of neutrophil migration into the gastrointestinal tissue due to an inflammatory process.<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> It is used for the diagnosis of inflammatory bowel disease, including ulcerative colitis and Crohn&#8217;s disease, for monitoring disease activity and response to treatment, for prediction of disease relapse and post-operative recurrence in inflammatory bowel disease, and for predicting those patients at highest risk of progressing to bowel resection.<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory guidance recommends that registration trials of potential therapies for ulcerative colitis use primary endpoints incorporating both endoscopy and patient-reported outcomes (PROs).<font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></font><font style="color:#2197D2;"> </font><font style="color:#000000;">Clinical trials for ulcerative colitis most commonly use </font>the Mayo endoscopic subscore (MES) and the composite Mayo Clinic Score. <font style="color:#000000;">FDA has consistently recommended the inclusion of endoscopic evaluation of mucosal healing in Crohn&#8217;s disease as a co-primary endpoint to ensure that a clinical improvement is accompanied by a benefit in the underlying disease process. </font>Simple Endoscopic Score for Crohn&#8217;s Disease (SES-CD) is a reliable and responsive instrument,<font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup></font> but correlates poorly with symptoms. The current regulatory recommendation for trial eligibility is an SES-CD score <font style="text-decoration:underline;">&gt;</font> 6 to define baseline endoscopic disease severity, with endoscopic remission defined by an SES-CD score of 0 to 2, and endoscopic response defined by a 50% reduction in the SES-CD score from baseline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">About Mesoblast </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62221615"></a>Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company&#8217;s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast&#8217;s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see <font style="text-decoration:underline;">www.mesoblast.com</font>, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">References / Footnotes</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Lightner A., et al. A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn&#8217;s colitis: A preliminary analysis. </font><font style="font-style:italic;font-size:9pt;font-family:Verdana;color:#000000;">Journal of Crohn's and Colitis</font><font style="font-size:9pt;font-family:Verdana;color:#000000;">, Volume 16, Issue Supplement_1, January 2022, Pages i412&#8211;i413, </font><font style="font-size:9pt;font-family:Verdana;text-decoration:underline;color:#000000;">https://doi.org/10.1093/ecco-jcc/jjab232.555</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Lightner A., et al. A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis. </font><font style="font-style:italic;font-size:9pt;font-family:Verdana;color:#000000;">Journal of Crohn's and Colitis</font><font style="font-size:9pt;font-family:Verdana;color:#000000;">, Volume 16, Issue Supplement_1, January 2022, Pages i398&#8211;i399, </font><font style="font-size:9pt;font-family:Verdana;text-decoration:underline;color:#000000;">https://doi.org/10.1093/ecco-jcc/jjab232.534</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Abreu MT and Sandborn WJ.&nbsp;&nbsp;</font><font style="color:#000000;font-size:9pt;font-family:Verdana;">Defining Endpoints and Biomarkers in Inflammatory Bowel</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.44%;color:#000000;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disease: Moving the Needle Through Clinical Trial Design.<font style="color:#000000;"> </font><font style="font-style:italic;color:#000000;">Gastroenterology</font><font style="color:#000000;"> 2020;159:2013&#8211;2018</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:57.7pt;">
<td valign="top"  style="width:10.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<br /><font style="font-weight:normal;">ABN 68 109 431 870</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.mesoblast.com</font></p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Headquarters</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Australia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;"> </font><font style="font-size:7pt;font-weight:normal;">+61 3 9639 6036</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +61 3 9639 6030</font></p></td>
<td valign="top"  style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">United States Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505 Fifth Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2060</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2061</font></p></td>
<td valign="top"  style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Asia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Biopolis Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#01-22 Nucleos (South Tower)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SINGAPORE 138567</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +65 6570 0635</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +65 6570 0176</font></p></td>
<td valign="top"  style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  BGCOLOR="#1266AE" style="width:10.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:9pt;font-family:Verdana;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:9pt;font-family:Verdana;">Daperno</font><font style="color:#000000;font-size:9pt;font-family:Verdana;"> M, et al. Development and validation of a new, simplified endoscopic activity score for Crohn&#8217;s disease: the SES-CD. </font><font style="font-style:italic;color:#000000;font-size:9pt;font-family:Verdana;">Gastrointest</font><font style="font-style:italic;color:#000000;font-size:9pt;font-family:Verdana;"> </font><font style="font-style:italic;color:#000000;font-size:9pt;font-family:Verdana;">Endosc</font><font style="color:#000000;font-size:9pt;font-family:Verdana;"> </font><font style="color:#000000;font-size:9pt;font-family:Verdana;">2004;60:505</font><font style="color:#000000;font-size:9pt;font-family:Verdana;">&#8211;512.</font><font style="font-weight:bold;color:#000000;font-size:9pt;font-family:Verdana;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Pathirana GW, et al. Faecal Calprotectin. </font><font style="font-style:italic;font-size:9pt;font-family:Verdana;color:#000000;">Clin Biochem Rev.</font><font style="font-size:9pt;font-family:Verdana;color:#000000;"> 2018 Aug; 39(3): 77&#8211;90.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">CDC Facts and Figures 2015</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Globaldata Pharmapoint 2018</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Dahlhamer JM, MMWR Morb Mortal Wkly Rep. 2016;65(42):1166&#8211;1169.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Crohn&#8217;s and Colitis Foundation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;font-family:Verdana;color:#000000;">Lightner AL. Surgery for Inflammatory Bowel Disease in the ERA of Biologics. </font><font style="font-style:italic;font-size:9pt;font-family:Verdana;color:#000000;">J Gastroinest Surg.</font><font style="font-size:9pt;font-family:Verdana;color:#000000;"> 2020 Vol 24: 1430-1435</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62221665"></a>This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast&#8217;s preclinical and clinical studies, and Mesoblast&#8217;s research and development programs; Mesoblast&#8217;s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast&#8217;s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including BLA resubmission), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast&#8217;s product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast&#8217;s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast&#8217;s ability to enter into and maintain established strategic collaborations; Mesoblast&#8217;s ability to establish and maintain intellectual property on its product candidates and Mesoblast&#8217;s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast&#8217;s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast&#8217;s financial performance; developments relating to Mesoblast&#8217;s competitors and industry; and the pricing and reimbursement of Mesoblast&#8217;s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast&#8217;s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release authorized by the Chief Executive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;text-transform:none;font-variant: normal;">For more information, please contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:89.48%;">
<tr>
<td style="width:44.72%;"></td>
<td style="width:44.76%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;">Corporate Communications / Investors</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;">Media</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paul Hughes</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sumit Media</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T: +61 3 9639 6036</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Titmus</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">investors@mesoblast.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T: +61 419 388 161</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">grant@sumitmedia.com.au</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rubenstein</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nadine Woloshin </p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T: +1 917-699-9456</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:9pt;font-family:Verdana;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E: <font style="text-decoration:underline;color:#000000;">nwoloshin@rubenstein.com</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:57.7pt;">
<td valign="top"  style="width:10.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mesoblast Limited<br /><font style="font-weight:normal;">ABN 68 109 431 870</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.mesoblast.com</font></p></td>
<td valign="top"  style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Headquarters</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 38</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55 Collins Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melbourne 3000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Australia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;"> </font><font style="font-size:7pt;font-weight:normal;">+61 3 9639 6036</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +61 3 9639 6030</font></p></td>
<td valign="top"  style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">United States Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505 Fifth Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2060</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +1 212 880 2061</font></p></td>
<td valign="top"  style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Asia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21 Biopolis Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#01-22 Nucleos (South Tower)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SINGAPORE 138567</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:7pt;font-weight:normal;"> +65 6570 0635</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">F<font style="font-size:7pt;font-weight:normal;"> +65 6570 0176</font></p></td>
<td valign="top"  style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  BGCOLOR="#1266AE" style="width:10.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:20.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:21.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:18.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#0F2E5A" style="width:8.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2x3wb0evosm000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2x3wb0evosm000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O 7L# 2(  A$! Q$!_\0
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M;8HR/ NS.6 (..O6IO"7A>QU;1X-;UR(:CJ-XN]I+CY@J]% 7IT [5J?$/\
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LH.V< ]/>NXTS3X-)TRVL+8'R8(PBYZG'<^YZU;HISJRFK/\ R%"E&#NC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g2x3wb0evosm000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2x3wb0evosm000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 ;(# 2(  A$! Q$!_\0
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M2:?XET/5I?*T_5[&ZEQGRXIU9ORSFLN5[EW1J4444AGBWQTU"]LK_11:7=Q
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M -&2USWAU_$?B'15\(:%"_DO.]S=,K;58$*HWGLHV].^?85T/QW_ .1XLO\
ML&I_Z,EKKO@-:Q+X5U*["+YTEZ8F;')544@?FY_.JYN6BF*W-4:."U+X-^*]
M.T^2\VV=R(UWM%;RDO@=< J,_0&L'P5XLNO"'B"&^B>0VK,%NH%/$J=^#QD=
M1_\ 7-?61&1@]*^+9E"3R*.@8@?G11FZJ:D%2*@TXGH:>$_&?Q.NY=?E$<<$
MS$0O=2%4"9/RH "=H]<<^YS7,^*?!NL^#[F*+5(4"S F*:)MR/CJ ?49'45]
M6:?:QV.FVMI"JK%!$L:*HP   !7 _&Z".3P")&4%HKN-D/ID,/Y&LZ==N:CT
M*G27+?J9?P6\8WFK0W6A:C/)<2VR>=!+(VYO+R 5)//!(Q]<=A7K=?.?P/8C
MQ[( <9LI ??YDKZ,K+$12GH:4FW'4XCXH^+)_"GA7?9.$O[N3R87QG8,99L>
MPX^I%> ^'_#FM^.M9EBM&,]QM\R>XN9#A1TRS<DG\S7HOQ^F8WFA0Y^58YGQ
M[DH/Z5S'PV\>V/@A=2^UV,]R]V8]IB(&T+NZY_WJZ*2<:7-%:F-1IU+2V-:3
MX#^(%AW1ZEIKR8^Z6<#\]M<.D^N^!?$LL<<LEGJ%I)MD56RK=\$=&4@Y_&O7
MO^%]Z/\ ] >^_P"^T_QKRGQUXCMO%7BB;5K6WD@26-%*2$$Y48SQ]!54W4;M
M-:"FH)7BSZ?\/ZLFO>'[#58U"BZA60J#G:Q'(_ Y'X5:O[M+#3KJ\D^Y;Q/*
MWT4$G^5<=\()#)\---!.=CS+_P"1&/\ 6NMU:S.H:-?62G!N+>2('TW*1_6N
M&22DT=*=XW/DK5-5U3Q3K1N;R:2YN[APJ+G@9/"J.PYZ5Z79_ 34);6-[S6[
M>"=AEHD@,@7VW9&?RKRJ&2YTC5HY-ACNK.<-L<?==&Z$?45[);_'Z$I_I/AY
MU;UCN@0?S48KOJ^T27LSEAR/XS@?'7P_O/ \EH9;N.[M[G<$E1"I#+C((Y]>
M.?6O3_@AXCO-4TB_TN]F>;[ R-"[G)"-GY<^@*\?7VI$^-WA>]*QW^DWJKG@
MM%'(J^_WL_D*[WPWK&@Z[9->:%);O'G;)Y<>QE/HPP"/QK"I.;A::^9K",>:
M\6;5>,?&SQ?>V=S;>'K"X>!)(?.NFC."X)(5,^G!)]<BO9Z^8OB],TOQ+U-6
M.5B6%%]AY2G^9-1AXISU*K.T3,\+>!-=\7B233($%O$VUYYGVH&ZX]2<'L*Z
M"_\ @KXLLK5YXQ8W95<F.WF.\_0,HR:]7^$$*1?#3374 &5YG;W/FLO\E%=S
M6D\1-2:1,:,7&[/D3PWXFU/PGJ\=Y8S.FUQYT!)"RKW5A_DBOK6TNHKZR@NX
M&W0SQK+&WJK#(_0U\G^-X$M_'6N11C"B]E('IEB?ZU])?#^4S?#_ $)B<D6B
M+^7']*,2DTI"HMIN)OW'_'K-_N'^5?*W@D:S?:E+H.B3>1-J@$4LX)!CC7YF
MY'0<<^O3O7U3<?\ 'K-_N'^5> _ FW63QC?3D9\JQ8#V)=/Z U-%VA)E5%>4
M4=I9_ SPU# JW5WJ%Q-@;G$BH,^P X_$FN<\;?""WT+1I]:T"]NLV8\V2&9@
M2%'5E8 8(Z\_G7N54-<A6X\/ZE X!62UE0Y]"I%1&M.]VRG3C;8Y#X3>++CQ
M/X8>._E\V^L7$4DA/S2(1E6/OP1[[<UWU>%? *8KJ^LP9^5X(W(_W6(_]FKW
M6E6BHS:0Z;O%-GAOQ^_Y"&A_]<IOYK7M=C_R#[;_ *Y+_(5XI\?O^0AH?_7*
M;^:U[78_\@^V_P"N2_R%.?\ #C\R8_'(GKYR\0IJ7Q&^+,^C+<F."&XDMXMV
M2D,<>0S >IVD^Y(&1V^C:X?Q)\0O"7A+4'AE3SM17[\=I"I=<_WF. /IG/M2
MI2:?NJ['42:U>AFV?P0\+01J+B2_N7'WF:8*#^"CC\ZY[QO\(--TC0;K6="N
M;J.6S7SFAE<,I4<G:< @@<]^GXUH_P#"^]'SQH]]_P!])_C5V7XI>&_%'AS6
M+"-I[6[EL)U2&Z0 2'RVX!!(_ XK1>V3N[D/V;5D6_A!XGN_$/A66&_F::ZL
M9?*,KG+.A&5+'N>HS[5Z%7BO[/Y.WQ"N> ;8X_[^U[56=9)5&D:4W>"/$?CM
MK]TEY8:##*\=NT/VF=5.!)EBJ@^H&TG'O6MHWP-T1=.@DU6[O9KMXP9%B=41
M6/4#Y<\=.3^%9/QV\/W3W=AK\,3R6ZP_9IV49$>&+*3['<1GV'J*V?#_ ,;-
M"DTFW36%N;:]C0+*4BWHY'=2.>>N#T]ZV][V:]G\S+W>=\Y9G^!OA:2/$5QJ
M4+=F693^8*UR/PRU34_#7Q&G\'S7#36;330E3]U70,0ZCMG;T]_:O0H?B[X*
ME95.K-&6_OVTHQ]3MKJ],UC3M:M?M.F7L%W"#@M$X;!]#Z'ZUFYS46IHOEBV
MG%EVO"OBA\.=,T/2;WQ%;W=V]U/>;FCD*[!O8DXP,_K7NM>>?&K_ ))[)_U\
MQ?S-31DU-6*J).+N<3X#^%.D>*O"EOJUY?7T4TKNI2%D"C:Q ZJ3VKKM-^"F
MA:9JEIJ$6HZBTEK.DR*[)@E6! /R].*O?!S_ ))O8_\ 76;_ -#-=[55*L^9
MJY,(1Y4[!1116!J%%%% !7A7Q]_Y"VB_]<)/_0A7NM>%?'W_ )"VB_\ 7"3_
M -"%;8?^(C.M\#/'Z**?%%)/*D42-)([!411DL3T '<UZ1Q'>?!S27U+Q_;W
M&#Y5C&\[G'&<;5&?JV?P-?2U<9\-?!O_  B'AS9<JO\ :5V1+<D<[?[J9]LG
M\2:[.O,KSYYW1VTH\L3YZ^.__(\67_8-3_T9+7:_ C_D1[W_ +"3_P#HN*N*
M^.__ "/%E_V#4_\ 1DM=K\"/^1'O?^PD_P#Z+BK>?\!&<?XK/4*^+KC_ (^9
M?]\_SK[1KXNN/^/F7_?/\Z,)U#$=#[/C_P!6OT%>??&K_DGLG_7S%_,UZ#'_
M *M?H*\^^-7_ "3V3_KYB_F:YZ7QHUG\+/-?@A_R/S_]>4G\UKZ-KYR^"'_(
M_/\ ]>4G\UKZ-K3$_P 0FC\)XA\?H6%UH4^/E9)DSCN"A_K5/X+:#HNO1:RF
MJZ=;W<D+0F/S5R5!WYQ^0KT+XJ>%;CQ3X4VV,?F7UG)Y\2#K(,$,H]R#GZJ*
M\ \/>)-8\%ZP]S8'R9P/+F@G0[7&?NLO!Z_0UK3]^CRQW,Y^[4N]CZ3_ .%>
M^$?^A?L?^_=<_JMI\+-$OVL=2M-+M[E "T;0L2 1D=!7$'X]:U]G*C2+ 3=G
MR^T?\!S_ %K@+B76O&_B62<0R7FI7; E(4Z 8 ^B@8Y/3N:F%&?VW9#E4C]E
M'U'X8?0GT2-O#@A&FEVV>2I5<YYX/O6C>7<%A937EU((K>!#)(YZ*H&2:R/!
MF@-X9\):?I,CAY84)E9>A=B6;'L"<?A6EJ^GKJVC7VG.Q5;JW>$L.VY2,_K7
M,[<QNKV//=6?X6^,M3B6>YMY-1N'6))(/,C=V)  .!@GH.<TDOP*\,.6,=[J
ML>>@$L9 _-,_K7AUY8ZKX2U]8[F)[6_LY5DC)7(RIRK+G@C(S7I]K\?KI+=5
MN_#\,TP'S/%=&-2?H5;'YUURISBE[-W1SJ<7\:,CXB?"V#PCI$>JZ=?33V_F
MB*6.<#<N<X8$8XXQC'>F_ ^\E@\<2VRL?*N+1PZ]LJ00?Y_F:RO&WQ+U/QI;
MQ6;VT5G8QOYGE1L69VQ@%F/7&3P .O?C':_!+PE?6UY<>(KV!X87A\FV61<&
M3)!+@>F  #WR?2JES*D^?<2LZGNGM5?,7Q>A:+XEZFS#"RK"Z^X\I1_,&OIV
MO%_C;X1O;NYMO$-C;O/''#Y-TL:Y* $E7QZ<D$]L"N?#R2GJ:UE>)UWP?F67
MX:::BD$Q/,C>Q\QF_DPKNJ^4/"WCW7?""2PZ9-&;>5M[P3)N3=C&[L0< =#V
MKH+WXV>++NW:*,6%J6&/,@A.X>XW,1G\*N>'FY-HF-:*C9G+^-IUN?'.N2I]
MTWTH!]<,1G]*^E? 41A\ Z$C#!-E&_\ WT,_UKYE\.>'=2\6:W'8V4<DCR.#
M-,02(E)Y=C_G-?6]M;QVEI#;0KMBA18T'HH&!3Q+22B*BFVY!<?\>LW^X?Y5
MX!\"9PGC.]A)QYM@V.>I#I_3->_W'_'K-_N'^5?+'@>76-,U.3Q#I%M]J.E@
M/<0#.7B;*MT[>_;@]JBBKPDBJCM*+/JRJ.MRK!H.HS.<+':RL<GL%)K@[+XW
M^%;B(&YCOK63'*O"&&?8J3_2N7\=_%ZUUO19]%T"VN<W0\N6>50ORGJJJ"2<
M].<=^.]1&C-NUBG4BE>Y%\ X2VM:Q/CA+=$)^K$_^RU[O7G_ ,)/"=QX9\,R
M3W\1BOK]Q(\;##(@&$4^_)/MNQ7H%%:2E-M!35HJYX;\?O\ D(:'_P!<IOYK
M7M=C_P @^V_ZY+_(5XI\?O\ D(:'_P!<IOYK7M=C_P @^V_ZY+_(4Y_PX_,4
M?CD%Y/\ 9;&XN,9\J-GP?89KY\^$6BVOB;QC?7VL1K>&",SE9@&#RNWWF!Z_
MQ'ZXKZ'EB6>&2)QE'4JP]CQ7SGHE[>_"+QU=1ZI9336DJ-#N7CS8]P*R)G@]
M.F>Y!P:JC=QDEN*INF]CZ(2SM8D"1VT*(.BK& !7)_$#PAI&L>%=2F:Q@2]M
M[=YX;B- KAE!;!/<'&#GUK.7XU^$##YADO5;'^K-O\W\\?K7->)/BA/XOL+O
M0?"NEW)\^)Q<7,X V0X.\X&0 1GDG\,D5,*=12OL5*<&K#?V?O\ F8O^W;_V
MK7M=>*?L_?\ ,Q?]NW_M6O:Z,1_$84O@1AZOXM\/:/?+IVJ:C##<2H"(75CN
M5B0.@QS@U6O/A]X2OF+3:!9 GJ8H_+_]!Q7FGQS\/WIU*R\06\4CVZP""9T'
M^J8,2I/IG=C/M[BM[1_CAH$]E$-4AN[6Z"#S=D>^,MWVD'./J*?LWRJ4!<ZY
MFI&V_P (O!#H571V0G^);J;(_-C7E6C+-\/OC,NDVUP[VS74=J^[^.*7:5W>
MXW*<^H_"O1+OXW>%((BT"WUR^.%2$+^98BO.?"\&H_$'XJIKK6K1V\=TEU.Z
M_<C5,;$SW)VJ/S-:4^>S]IM;J1/ENN7<^CJ\\^-7_)/9/^OF+^9KT.N1^)FB
MW.O> [^ULXS)<IMFC0=6VD$@>^W.!ZUSTW::;-IJ\64/@Y_R3>Q_ZZS?^AFM
M3QAX]TOP4UF-2M[R7[6',?V9%;&W;G.YA_>%>6_#/XFZ;X8T5]&UF*=$25I(
MIHDW  ]589SUS^=9WB_7'^*GC+3=/T2VF6",>6C2+R-Q&^1@#PH 'Y>^*W]D
MW4;EL9>T2@K;GT/;SI=6L5Q'G9*@=<]<$9%%.AB6&&.)/NHH4?045RFX^BBB
M@ KPSX\QO+K6BI&C.Y@DPJC)/S"O<Z*NG/DES$SCS*Q\I:)\//%.O.OV72IH
MH2>9[D>4@'KSR1] :]P\#?"_3?"++>W#K?:ICB9EPL7J$'K_ +1Y^G-=[15U
M*\IJQ,*48ZA1116)H9U_H&C:K.L^HZ387DRKL$EQ;)(P7).,L#QDGCWJ>PTV
MPTJ!H-.LK:SA9MYCMXEC4M@#.% YP!S[476HV=E-;0W-S'%+<OY<*,>9&] .
M]9>L^++'0M4LM/N[>]+WKI'#+'!F,NS8"[LXSWQZ52YGH+1:F]6*?!_A@DD^
M'-()/4FQB_\ B:VJ*2;6P63#H,"J][866I6_V>_M(+J D,8YXPZY'0X(Q5BB
MD,S;'P_HNF7'VC3]'T^TFVE?,M[9(VP>V0,XK2HHH;;W *H:AH>DZM@ZCIEG
M=D=#/ KD?B15^BB]@.=_X0/PGYF__A'=.SZ>0N/RZ5L6.FV&F0^3865M:1_W
M((E0?D!5JBFY-[BLD%%%%(96O-/LM1A\F^L[>ZB_N3Q*Z_D16-)X"\)R$%O#
MVG#']V +_*NBHIJ36PFDS(M/"OAZPF$UIH>G0RCI(EL@8?0XS6O4-U=6]C:R
M75U,D,$2[GD<X51ZDTR2_M8M-;47F M$A,[2X. @&[/KTYHU8:(LT54TO4[3
M6=-@U"PE\VUG7=&^TKGG'0\]0:MTMAF1>>%O#^H2F6\T33IY2<EY+9"Q_'&:
MJIX$\)QDE?#NFG)S\UNK?SKH:*?,^XK(@M;.UL8!!:6T-O$.D<*!%'X"IZ**
M0Q" 000"#U!JC8:'I.E2/)IVEV5F[C:[6]ND98>AV@9J_11<#"O/!?AG4)S/
M=:%822L<L_D*"WU(ZU-IOA70-(F$VGZ/96\PZ2I"N\?\"ZU>U"]73[":[:">
M=8EW&.WC+NWT4=:H:/XET_6] .MVYDCL0')>9=I 3.XX&>.#^55>37D*RN;%
M%4]*U2SUK3(-1T^7S;6<$QOM*YP2#P>>H-6V8*I9B H&23VJ=AE+4-%TK5FC
M;4M,LKQHP0AN;=9"N>N-P.*NJH50J@!0,  <"J&C:UI_B#3EU#3)_/MF8J'V
M,O(.#P0#6A3=]F)6W"JU]IUEJ=N;>_LX+J$G/ESQAU_(U9HI#.:/P^\(DD_\
M(]8<G/\ JJV;72--L;-[2TT^U@MG!#PQ0JJ,#UR ,&KE%-R;W8K)%+3]&TO2
M?,_LW3;.R\W'F?9H%CWXSC.T#.,G\ZNT44KW&(0&4JP!!&"#WK"NO!/A>\D,
MD^@:<SDY+"W52?KCK6]133:V$TF<XG@#PE&X9?#VGDC^]"&'Y&MZWMH+2!8+
M:"."%?NQQ(%4?0"I:*&V]P22V"BBBD,QM0\)>'M5G:XOM%L9YV^]*\*[V^IZ
MFK.F:'I.BJRZ9IMK9[\;S!$%+8Z9(Y/XUH44[NUA604444AA1110 4444 %%
M%% !1110!YCXBM=;U/XKZ79V^I6J-:6TM[;[K8L(5;Y/F&[YB2!Z8IWC>ZNE
M\8>#]/5%O;V'?<>6!L$LN $;OM4,&8^@!ZUJ7-AX@L?B8^L6NDQWUA=V\5JT
MWVE8VMDW L<'ENYP.O%7XM!NY?B9/KUS&OV2'3UM;5MP)+%MS''4=2/QK?F2
MMZ&=OS*7AK7-=;QAK.B:U<6=PEG!'-YMO&8Q&6 .WD],'OZ5@7_Q!U*]T^ZU
M;2M3TRUACG,5CI\D?FW%]@@9P&RH)/  ^I[UTND^'+Y=4\77EWB%]6?RK=PP
M8B-4*JW'3KT]JR?!VG^(O#\=EI<O@^P7R6V2ZJEW&"Z%N6VA=Y.#WZX[4+EW
M]/\ @AKL>@6DDTUE!+<1>5,\:M)'G[C$<C\#7GEUXC\5MX\O_#.GW%E/)Y8D
MC=K<JMLK$-N?D[MJD#W+#MFO2:Y7PUH5Y9>)O$FL7\2K)?W"K 0P8^2@PIXZ
M9XX]A6<&E=LJ2>AF:MXMNXM8_P"$?@U?3;&6SM5DU#4[P#:'(&%1,@%CUZX&
M<4W3?'-];^ 9-<U:U6:X-R;>R6%3']MR0$8 \C//X*3BJ\VB:YH_C+5]1M_#
M%GKT&H21R12R7$<3V^!@CYP3^7H*TO&VEZYJVBZ)=65C%+?V-]#>2V0F 5BH
M.5#' ."<=N,UI:.B)UU9FWNK>,]*UC0(+[4M.:;5;E8WLH+;B)!@N0Y.3@'%
M6M;\932>(KS1K#5=.TJ&PB#7=_> /\[=$1"1D^IY]/KFVEMJ&H_%_3Y]6V+>
M6MA)<M;PONCMU;*)'GNWS%B>^1V J2/0]>T'Q3K%W!X7LM=AO[K[1#<R7,<3
MP9_A.X$X&>WI[T[1Z[V%=DS>*O$+?"UO$4CVUI>0L6+/;DK<1YVJ0I(*[B5Y
M_3FJESXM\6IHVBZVOV&.TNKB"W$#Q'S+DL.7Z_*I()4=<8)]*Z/QGH^J^)/"
M%OIL<$:7%S+!]L591MC4$,^">N"!CUI_B30;K4]3\,PVL"?V;878N9_F V;!
M^[ '?O4IQ[=QM,@\3^+)++7;;0;"[L;.YDB-Q<WEZP\NWB' XR-S$]LU2T+Q
M%KNI^&-=N&O;0FQE86NIBV/EW")RS;,C/ (R#CGOCF+6M"UFS\=7>NVGAZTU
M^UN[=(Q#--'&T#+CD%P>#CMZ^U;VLV^LZKX!O;5;"&WU.YMWA%JDX94#';C?
M@#[O/Z4>ZDK!K=F#X3\3^(=7TB+7]4FM;;1K6&1[AA%A[@C=G;_=5>!ZD@]J
MHZKXH\6KX4E\6K=66FV!VM:V+0>;)*C$!2S$\$YSQVKI[_PW/_PK.3P]9;?M
M*V @0$X#. ,\^YS^=<AK'AOQAXB\,Z7;76EV\*6+1(-/6Z7]X%&&D9N@X 4*
M,XW,3T%5'E;OIO\ @)W2L:'Q(.L3^#M,M#>0HVHR6]I/$(3NDE8AL@Y^494\
M8-7O%%YX@\*>!9;TZG933VSJ"/L>%="50(!NXQDG//TJ3QEIVOZG!X=U"QTN
M*>YL;I+JXL#<J/F ' <X!P<\_I4WBS2-6\3Z#HUK]C2%GO()M0A,RL(HQRZY
M_BP3VZXJ4U:*8VGJ1WNNZGHOB#PCIT@@6UU"-HKE5BQB54'W?0;F''M3(_%]
MQ)K_ (@O3(J^'-%@\IR$!,UP.6"GV^[CZ>M3?$30-6UK3]-FT-4.HV-ZL\99
M@N  <]??;4=WX'=/A?-X8L)5%T\2LTK'B27<'8D^Y&/88H7)97!\US"3QOK]
MQ+HUW;WVES2:C<HO]BP)YDL<#<[V<'(( YR !GVQ7J3;BC!2 V."1T-<?X3_
M +<MI8+2Z\'V6DP)&$FNH;J,^80O&$0=R!U/&:[ D@$@9..GK4U+7LBH['F>
ME^)O%FJ7NMZ5:W=A)-I\S1O>O;E(XE7.?ER<LS9 YP A/I56W\<>*=7\"2:W
M9BSM!8Q,;J>6,MY\@;[L:] -NTDGNV!T-;6@^&=7TOP!K-N\2#7-2:XE8+(,
M!W!5?FZ>_P"--U+PAJ*_":V\,:?$@NV2)9_G  .X/(<]^<_6M+PO\_\ AR+2
ML6=7\:W&F^%]"F\JW&L:Q'$(DF;9%&S*"SMWVKN''O4/AGQ-J=SXFU&RNM2L
M=4TNUM?/?4;6'8D3Y'[O()!XR>IZ?6G>,/#FH3:MH.J:;I=MJL.FK)&]A/(J
M!PR@ @L,<8SSZ"M-+?5M7\':I83Z/;Z-//;206]O'<+(%W(0"2H ')[5/N\O
MJ/6YS&I^(O$NJ^$M1\26UU::5HRQO]FBDA\R:=>5!8DX7<>F/UZF1YK_ ,(_
M!K3KNPF@@>WMXY94FA\SS#*<[>HP=S]>>E9E]X9\9ZWX!M=%GTZ"S%DD<26Z
MW*EIRN!O8@X"@ _+DY)SV%=5XGT;5?$/AC2=.6PBM]UW"U[!YX<1PJ3D!L#=
M_#T%4^5672XM=PU7Q!J6FV^AZ'IEO;2:]J$0)#KMA@"J"[E1VSG ]OP)JTWB
MC0O!^HW]UK%C+=V^9E<6F%*!?N8W=2V!GT[5%XDTC7[?QO8^)]%LH=1$5H;2
M6T>81-C<3N#'C^+]/>K'BS3M=\2> GT];2*WU"Z=!-$LX98U#@GYN,\ ?G4J
MVA6NIE^(?$&LZ%\/-(UBVGLK6>2.+SX6MLJSR ' P?EQ\Q/!S2S^)/%-KXC\
M._:4M(K+5YC&+$H?.C0 ?,S9^]@Y(' Z<]:U?%_ARZUR;P[900(VFVMZL]UN
M8#"H, 8/7.2*DU/1+_4/B+HNIF-?[-TZVE(<N,F5P5QCKTP<T)QMKYB:=S/U
MWQA*WB&ZT6PU33M*CL8@]W?WN&P[<JB(2,G')//I]=7P+K.I:]X9COM4A1)F
MD98W1"@FC'W7 /(S_2N<?1==T7Q=K%_!X6LM=@OYEFAG>XCB># Y!W@G\O2O
M0[5IWLX6N8UBN&C4RQHVY5;'(![@'O2G91LAQO?4YGQ%XAU)->L_#F@1V[:G
M/&;B::XR8[>$'&X@=23P/_KU6U+7-;\-Z=9V%Q+;:KK^HW)BLPL?E1A<#+.!
MV7J<>OXU7UG3/$>E^/F\2:-IL.JPW%D+62!KA86C(8'(+<8X'YFE\2Z3XCN[
M_P .^(K"RMY=0TY9#/8-. "74 A7/''(S]*:4=!-O42'6O$^B>,=)TG7)[&]
MMM5$@1K:(HT+(H)^HY'7U[8Q567Q-XF7Q]?^&[26RNY/*WPDP%%MPQ!W2$$D
MA5(';)9>E:NE:'K&I^*8O$GB*."V>UB:*QL89/,$6X89V;H6(R../RJ?PWH=
MY9>)/$FLWT*B6^N%6WPX),*#"_3/''L*+Q7W?B%F<[HWBGQ7K$>K:7 ]C]NT
MZZECFU%XR(EC7A<)GEF(;'8 <]LW;'Q1K6H?"?\ X2/S[:WOHHY968P[ED"%
MA@+D8)P!FGZ#X:U?2_A[J]J\2#7-1-Q*X608$CY5?FZ=,&L[Q38W&A?!RRT%
M5 OKC[/9A%8<RLP9E!Z<D,*KW6[+N+5*[*MYXT\71^"[/Q.@LH[1#&'B>([[
MHDX8C^ZN>!W."<XQ75:]XAU-_$-OX;\/1P?V@\/VBXN+@$I;19QT'5B>WN/7
M(RTT#7?$BZ39:MIEOH^B:<R2&S2X$\DY08525 4+_GZ+=Z3XIL?B%JNHZ39V
MTUOJ=O%&MU-* MJ5 !RO5NF<#KD<]:7N^0]2UX/U?6[WQ)K^EZCJ$%]%IGEQ
MK/';B/=(P)(P#VP165HWB3Q9JVLZUHEO=6$LUC-Y;7S6Y6.$#(.5R=S,> ,\
M;6)[5I^ -!U;P]<ZO!?60$-S<-.EV;@.\O0 ,H'4\L3GJ>E.\->']5TCPCK7
MF0(NM:A+<7&T2 C>P.P;NF/\30W%-_(%?0QT\;>()?A(/$R"#[=#/B3]U\LD
M>_9G'8\CIZ5T.O>(;QM4\/:5HDBK<ZC(+B9R@;R[91EB0>F>@/L:R[W1_P"P
M/@E<Z9=[8Y(;!O,&X$>8Q+8SW^8XIWPUTF\>T_X2/54VW=U;16]LAZQ6Z* /
MIN(W'\#WH?+9R\V"OHCOZ***P- HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\A^,/B+6-#UC2AI>HW%JK0.66-\*QW#DCH:**VPZ3J),SJNT39^$,:W
M7AZXUFY+S:E=SLL]S*Y9W"\*,GL/:O1:**FK\;*A\*"BBBLR@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X
MCQ[\^L>#XFY0ZQ&Q7W X-%%73^(F6QV]%%%04%%%% 'CMQ=7&O?&>;0-4GDN
F=(BEWI9NY$>5C##('7GL<U[$!@8'2BBMJWV?0B'7U"BBBL2S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>glqsvqcpzqcz000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glqsvqcpzqcz000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  )  ,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
